127 related articles for article (PubMed ID: 25138574)
41. Effect of pioglitazone on testosterone in eugonadal men with type 2 diabetes mellitus: a randomized double-blind placebo-controlled study.
Sridhar S; Walia R; Sachdeva N; Bhansali A
Clin Endocrinol (Oxf); 2013 Mar; 78(3):454-9. PubMed ID: 22816533
[TBL] [Abstract][Full Text] [Related]
42. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus.
Kanazawa I; Yamaguchi T; Yano S; Yamamoto M; Yamauchi M; Kurioka S; Sugimoto T
Osteoporos Int; 2010 Dec; 21(12):2013-8. PubMed ID: 20130841
[TBL] [Abstract][Full Text] [Related]
43. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
[TBL] [Abstract][Full Text] [Related]
44. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes.
Perez A; Khan M; Johnson T; Karunaratne M
Diab Vasc Dis Res; 2004 May; 1(1):44-50. PubMed ID: 16305056
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
Perez A; Zhao Z; Jacks R; Spanheimer R
Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
[TBL] [Abstract][Full Text] [Related]
46. Pioglitazone reduces monocyte activation in type 2 diabetes.
Pitocco D; Giubilato S; Zaccardi F; Di Stasio E; Buffon A; Biasucci LM; Liuzzo G; Crea F; Ghirlanda G
Acta Diabetol; 2009 Mar; 46(1):75-7. PubMed ID: 18820825
[TBL] [Abstract][Full Text] [Related]
47. Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes.
Esteghamati A; Ghasemiesfe M; Mousavizadeh M; Noshad S; Nakhjavani M
J Diabetes Investig; 2014 May; 5(3):327-32. PubMed ID: 24843782
[TBL] [Abstract][Full Text] [Related]
48. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Biomed Pharmacother; 2009 Dec; 63(10):723-33. PubMed ID: 19906504
[TBL] [Abstract][Full Text] [Related]
49. Effect of pioglitazone on energy intake and ghrelin in diabetic patients.
Martin CK; Gupta AK; Smith SR; Greenway FL; Han H; Bray GA
Diabetes Care; 2010 Apr; 33(4):742-4. PubMed ID: 20067964
[TBL] [Abstract][Full Text] [Related]
50. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
Esteghamati A; Eskandari D; Mirmiranpour H; Noshad S; Mousavizadeh M; Hedayati M; Nakhjavani M
Clin Nutr; 2013 Apr; 32(2):179-85. PubMed ID: 22963881
[TBL] [Abstract][Full Text] [Related]
51. Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trials.
Chen R; Yan J; Liu P; Wang Z
PLoS One; 2015; 10(4):e0123703. PubMed ID: 25897968
[TBL] [Abstract][Full Text] [Related]
52. Intake of traditional Inuit diet vary in parallel with inflammation as estimated from YKL-40 and hsCRP in Inuit and non-Inuit in Greenland.
Schæbel LH; Vestergaard H; Laurberg P; Rathcke CN; Andersen S
Atherosclerosis; 2013 Jun; 228(2):496-501. PubMed ID: 23591413
[TBL] [Abstract][Full Text] [Related]
53. Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study.
Jianfang F; Wanxia X; Xiling G; Jing X; Wenjuan Y; Jianrong L; Qingzhen H; Kaiyan M; Jingxuan L; Taixiong C; Qian X; Mengying L; Jie M; Qiuhe J
J Diabetes Res; 2023; 2023():2044090. PubMed ID: 37305429
[TBL] [Abstract][Full Text] [Related]
54. Anti-diabetic combination therapy with pioglitazone or glimepiride added to metformin on the AGE-RAGE axis: a randomized prospective study.
Ragazzi E; Burlina S; Cosma C; Chilelli NC; Lapolla A; Sartore G
Front Endocrinol (Lausanne); 2023; 14():1163554. PubMed ID: 37635976
[TBL] [Abstract][Full Text] [Related]
55. Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes.
Nakatsuji H; Kishida K; Funahashi T; Shimomura I;
Atherosclerosis; 2010 Sep; 212(1):243-5. PubMed ID: 20541758
[No Abstract] [Full Text] [Related]
56. Effects of pioglitazone and metformin on abdominal adhesion formation in an experimental model.
Yücesoy MA; Hatipoğlu E; Balık OA; Yanar K; Batur Ş; Şimşek O; Apaydın BB
Ulus Travma Acil Cerrahi Derg; 2024 Jun; 30(6):406-414. PubMed ID: 38863295
[TBL] [Abstract][Full Text] [Related]
57. Effects of pioglitazone on the differentiation and inflammation in vitiligo keratinocytes.
Bastonini E; Kovacs D; Briganti S; Ottaviani M; D'Arino A; Migliano E; Pacifico A; Iacovelli P; Picardo M
J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):e573-e575. PubMed ID: 38305589
[No Abstract] [Full Text] [Related]
58. Correction: Comparison of the efficacy of pioglitazone and metformin on ultrasound grade and liver enzymes level in patients with non-alcoholic fatty liver disease: A randomized controlled clinical trial.
Khoshbaten M; Beheshtirouy S; Shayanrad S; Gharekhani A; Rezaee H
Drug Res (Stuttg); 2023 Apr; 73(4):e1. PubMed ID: 37369353
[No Abstract] [Full Text] [Related]
59. Erratum. Individualizing Treatment of Type 2 Diabetes After Metformin: More Insights From GRADE. Diabetes Care 2024;47:556-561.
Riddle MC
Diabetes Care; 2024 Jun; 47(6):1099. PubMed ID: 38564373
[No Abstract] [Full Text] [Related]
60. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study.
de Leeuw PW; Notter T; Zilles P
J Hypertens; 1997 Jan; 15(1):87-91. PubMed ID: 9050975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
